Q-omics provides the consensus-scored SLC10A6 profile across patient tissues and cancer cell-line models. SLC10A6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC10A6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC10A6 RNA expression shows 17,540 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SLC10A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC10A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC10A6 survival associations across molecular data types. SLC10A6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC10A6 RNA expression–survival associations across cancer types. High SLC10A6 expression shows unfavorable associations in KIRP, LGG, BLCA, THCA and STAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC10A6 RNA expression.
This table summarizes SLC10A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC10A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC10A6 shows lower tumor expression in BRCA, UCEC and THCA and higher tumor expression in KIRC, LIHC and LUSC. The KIRC box plot shows higher SLC10A6 RNA expression in tumor versus normal tissue (log2 FC = +1.565, t-test p < 0.001).
This table shows molecular features associated with SLC10A6 in patient tissues and cancer cell lines. In patient samples, SLC10A6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC10A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
